title: [Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid].
abstract: We aimed to determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS)with Sonazoid in the evaluation of early response to sorafenib for hepatocellular carcinoma (HCC). Thirteen ad- vanced HCC patients with low a / -fetoprotein (AFP) level (≤35 ng/mL) who received sorafenib for at least 4 weeks were enrolled in this study. CEUS was performed before and after treatment (2 weeks), and the images of the target lesion in the arterial phase were analyzed by AtPI. In the color mapping images obtained by AtPI, the mean arrival time of the contrast agent in the target lesion from the starting point (mean time: MT) was calculated. In each patient, differences between MT before and MT 2 weeks after treatment were compared. MT (+) and MT(-) groups were designated as such if the difference was 0 or greater(blood flow velocity of the lesion was reduced)and less than 0 sec(blood flow velocity of the lesion was increased), respectively. The overall survival was evaluated between the 2 groups. In the MT (+) group (7 patients) and MT (-) group (6 patients), the median survival times were 307 and 208 days, respectively, which was statistically significant. We suggest AtPI is useful for evaluating early response to sorafenib in advanced HCC patients with low AFP level.
authors.affiliation: Division of Gastroenterology and Hepatology, Dept. of Internal Medicine, Toho University Medical Center, Omori Hospital.
authors.forename: Kazue
authors.initials: K
authors.lastname: Shiozawa
authors.forename: Manabu
authors.initials: M
authors.lastname: Watanabe
authors.forename: Takashi
authors.initials: T
authors.lastname: Ikehara
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Matsukiyo
authors.forename: Michio
authors.initials: M
authors.lastname: Kogame
authors.forename: Mie
authors.initials: M
authors.lastname: Shinohara
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kikuchi
authors.forename: Masao
authors.initials: M
authors.lastname: Shinohara
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Igarashi
authors.forename: Yasukiyo
authors.initials: Y
authors.lastname: Sumino
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000737:chemistry / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003287:Contrast Media; D005260:Female; D005290:Ferric Compounds; D006801:Humans; D007501:Iron; D008113:Liver Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010087:Oxides; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D000077157:Sorafenib; D013997:Time Factors; D014463:Ultrasonography; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D005290:Ferric Compounds; D010087:Oxides; D010671:Phenylurea Compounds; C069727:Sonazoid; D000509:alpha-Fetoproteins; D009536:Niacinamide; D000077157:Sorafenib; D007501:Iron